Phase 3 Trial of Masitinib Again Enrolling ALS Patients in Norway
A national agency in Norway has given AB Science the go-ahead to resume enrollment in AB19001, a Phase 3 clinical…
Articles by Marisa Wexler, MS
I AM ALS Expanding Efforts Into Research, Patient Support
I AM ALS, a nonprofit dedicated to helping people affected by amyotrophic lateral sclerosis (ALS), is expanding its…
Defects in Cholesterol Metabolism, Due to TDP-43 Protein, Tied to ALS
Defects in cholesterol metabolism may account for some of the neurological damage that occurs in amyotrophic lateral sclerosis (ALS)…
Masitinib, Given Early in ALS Course, Extends Life, Trial Data Show
Treatment with the investigational oral therapy masitinib can extend lifespan when given early in the course of amyotrophic…
Childhood Form of ALS Identified, Linked to SPLTC1 Mutations
A previously unknown form of amyotrophic lateral sclerosis (ALS) — one with onset during childhood — is caused by mutations…
Nearly $12M Grant Will Fund ALS Cell Therapy Trial at Cedars-Sinai
Cedars-Sinai Medical Center, in California, has been awarded an $11.99 million grant to support a clinical trial that will test…
Rare 2030 Action Campaign Pushing for European Plan for Rare Diseases
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
MediciNova Secures European Patent for MN-166 Plus Riluzole
The European Patent Office will grant MediciNova a patent that covers the combination of MN-166 (ibudilast) and riluzole…
#AANAM – Trial Will Evaluate Tofersen in Presymptomatic SOD1 Patients
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22.
3D Imaging System May Have Applications in ALS Research
A novel system for three-dimensional (3D) imaging of zebrafish may be useful for studying the motor and neuronal deficits linked…